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Abstract
Cytokine expression was assessed during antigen-induced
arthritis (AIA) in synovial membrane (SM), inguinal lymph node
(LN), and spleen using competitive RT-PCR and sandwich
ELISA. In the SM, early elevations of IL-1β and IL-6 mRNA (by 6
hours; 450- and 200-fold, respectively) correlated with the joint
swelling; a 6-fold increase in tumor necrosis factor α (TNFα)
was not significant. Not only IL-2 and IFN-γ (which increased
10,000-fold and 200-fold, respectively), but also IL-5 and IL-10,
increased acutely (6 hours – day 1; 3-fold and 35-fold,
respectively) in the SM. In general, the protein levels in the SM
for IL-1β, IL-6, TNFα, IFN-γ, IL-4, and IL-10 (increase from 4-fold
to 15-fold) matched the course of mRNA expression. In the
inguinal LN, there were early mRNA elevations of IL-6 (a 2.5-fold
increase by 6 hours, which correlated positively with the joint
swelling) and IL-2 (4-fold by 6 hours), as well as later rises of IL-
4 and IL-5 (2.5- and 4-fold, respectively, by day 3). No significant
elevations of the corresponding proteins in this tissue were
observed, except for IL-1β (by day 6) and IL-10 (by day 1). In the
spleen, there were significant mRNA elevations at 6 hours of IL-
1β (1.5-fold), IL-6 (4-fold; positively correlated with the joint
swelling), IFN-γ (3-fold), and IL-2 (7- to 10-fold). IL-5 and IL-10
(2- and 3-fold, respectively) peaked from 6 hours to day 3 in the
spleen. Increases of the corresponding proteins were significant
in comparison with day 0 only in the case of IL-2 (day 6). By day
6 (transition to the chronic phase), the mRNA for cytokines
declined to or below prearthritis levels in all the tissues studied
except for IL-1β in the SM and IL-6 in the spleen. AIA is thus
characterized by four phenomena: early synovial activation of
macrophages, T helper (Th)1-like, and Th2-like cells; late, well-
segregated Th2-like responses in the inguinal LN; late,
overlapping Th1-like/Th2-like peaks in the spleen; and chronic
elevation of synovial IL-1β mRNA and spleen IL-6 mRNA.
Introduction
CD4+ T helper (Th) cells and macrophages infiltrate the
synovial membrane (SM) during the course of rheumatoid
arthritis (RA) [1-3]. Both cell types, when activated, appear
to play a central role in promoting and maintaining the dis-
ease process [4,5], for example by producing certain sets
of cytokines that influence the quality and extent of the
inflammatory process [6]. Cytokines, in turn, can elicit the
production of tissue-degrading enzymes, a mechanism
eventually involved in tissue destruction and loss of articu-
lar function [5,7].
Many studies indicate that Th cells differentiate into func-
tionally polarized effector subpopulations, producing either
Th1- or Th2-like cytokines [8,9], although this concept has
recently been re-evaluated [10] in a report that focused
attention on the specific role and effects of individual
cytokines. The Th1/Th2 subpopulations nevertheless
appear differentially involved in several human and experi-
mental immunological disorders, exerting either proinflam-
matory or regulatory functions [11]. Thus far, however, the
evidence as to the expression of these cytokines in human
RA is relatively limited and/or contradictory [12,13] and
AIA = antigen-induced arthritis; ELISA = enzyme-linked immunosorbent assay; IFN = interferon; IL = interleukin; LN = lymph node; mBSA = methyl-
ated bovine serum albumin; PBS = phosphate-buffered saline; RA = rheumatoid arthritis; RT-PCR = reverse transcriptase polymerase chain reaction; 
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does not provide information on the time course and organ
distribution of the cytokine profiles. Indeed, an extensive
study of longitudinal cytokine profiles in RA is complicated
by the influence of disease phases and/or treatments [14],
most of which affect proportions and functions of lym-
phocytes and macrophages (reviewed in [1,2]). Experimen-
tal models of arthritis are therefore well suitable for learning
about the sequence of cell activation in well-characterized
phases of the disorders.
Antigen-induced arthritis (AIA) in the rat [15], a severe knee
monoarticular arthritis induced by intra-articular administra-
tion of methylated bovine serum albumin (mBSA) after sys-
temic immunization, is a suitable arthritis model inasmuch
as CD4+ T cells and macrophages infiltrate the SM [16]
and its course consists of clearly discernible phases. The
acute phase progresses within approximately 1 week into
chronicity, that is, a status of low-grade inflammation with
moderate joint destruction and bone formation [15].
Because of its prominently local character, AIA is a unique
model for the analysis of cytokine patterns in locally driven
immune responses, and also a useful counterpart for com-
parison with more systemic models of arthritis, such as
adjuvant- and collagen-induced arthritis [17].
To elucidate the sequence and the interplay of cytokine
gene activation in AIA, therefore, the mRNA expression of
monokines and of Th1-like and Th2-like cytokines was ana-
lysed in the SM, regional lymph node (LN), and spleen of
diseased rats by means of semiquantitative, competitive
RT-PCR. To assess local translation into protein, the
cytokine levels were also measured by ELISA. The analysis
was carried out in mBSA-immunized animals before induc-
tion of disease (day 0), at 6 hours after injection of the
arthritogen, and on days 1, 3, and 6 of the disease, the lat-
ter time point marking the transition to the chronic phase.
For the sake of clarity, individual cytokines are assigned to
monokine- and Th1-/Th2-like patterns, according to widely
accepted schemes [8] and/or their prevalent cellular
source in arthritis [2,18].
Materials and methods
Animals
Induction of arthritis
Female Lewis rats (140–190 g, age 7 to 10 weeks,
Charles River Laboratories, Sulzfeld, Germany, or Animal
Research Facility, Friedrich Schiller University) were immu-
nized 21 and 14 days before induction of AIA with 2 ml
(total volume) of a suspension containing 1 ml each of
mBSA dissolved in PBS (500 µg/ml; Sigma, Deisenhofen,
Germany), and complete Freund's adjuvant (2 mg/ml
Mycobacterium tuberculosis; R37 Ra; Difco, Detroit, MI,
USA) by multiple subcutaneous injections into both flanks
of the animals. On day 0, AIA was induced by intra-articular
injection of 100 µg mBSA in 50 µl of PBS into the right
knee joint; the left knee received 50 µl of PBS and served
as control. All animal studies were approved by the govern-
mental commission for animal protection.
Scoring of arthritis
The disease course was monitored by repeated assess-
ment of the bilateral swelling of the knee joint using a cali-
per (Kroeplin Längenmesstechnik, Schlüchtern, Germany).
The swelling was expressed as the difference between the
arthritic (right) and the control, unaffected joint (left).
Assessment of cytokine mRNA expression
Tissue sampling and preparation
Samples of knee joint SM, inguinal LN, and spleen were
obtained from rats killed at five time points: day 0, 6 hours,
day 1, day 3, and day 6 of AIA (four to six rats per time
point). After sacrifice, tissue pieces (approximately 2 to 5
mm3) were excised, snap-frozen in 500 µl guanidinium thi-
ocyanate buffer, and kept at -70°C until processing.
Semiquantitative RT-PCR
Frozen tissues were homogenized, mRNA was isolated,
cDNA was prepared and competitive RT-PCR was per-
formed as previously described [19]. Quantification was
not done until all cDNAs had been adjusted to equal β-actin
mRNA content using semiquantitative RT-PCR with a com-
petitor fragment, which contained the sequences corre-
sponding to the primers [20]. From the present data, there
was no experimental indication for the regulation of β-actin
under arthritis conditions. In addition, the consistency
between values found for mRNA (normalized to β-actin)
and for protein (normalized to total protein) in the SM sug-
gests little or no regulation of β-actin in this system. An
amount of 2.5 × 10-12 to 2.5 × 10-19 moles, corresponding
to 1.5 × 1012 to 1.5 × 105 molecules and to a dilution from
10-3 to 10-10 of the competitor fragment, was added to
each PCR assay as an internal standard. Relative quantifi-
cation of specific cDNAs was carried out as previously
described [19]. The highest dilution at which the competi-
tor fragment was still detectable for each particular
cytokine PCR was arbitrarily defined as 1 unit; the dilution
at which cDNA was detectable and the density of the band
of the resulting PCR product in agarose gels were used to
express the results as multiples of 1 unit. To guarantee
reproducibility of the results, PCR was performed in dupli-
cates, which yielded comparable results.
Assessment of cytokine protein expression
Tissue sampling and preparation
In an independent AIA study, samples of knee-joint SM,
inguinal LNs, and spleen were obtained from rats killed at
six time points: day 0, 6 hours, day 1, day 3, and day 6 of
AIA. Cytokine protein analysis was performed on five to six
rats per time point. The tissue pieces were snap-frozen in
250 to 1000 µl PBS–EDTA (0.9% NaCl, 30 mM KCl, 70Available online http://arthritis-research.com/content/7/3/R445
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mM Na2HPO4, 10 mM KH2HPO4, 10 mM
ethylenediaminetetraacetic acid) containing a proteinase
inhibitor cocktail (Complete®; Roche Diagnostics, Man-
nheim, Germany), and kept at -70°C until processing.
Immediately after thawing, tissue pieces were homoge-
nized using an Ultra Turrax and centrifuged Subsequently
the supernatants were divided into aliquots and kept at -
70°C.
Sandwich ELISA
Concentrations of IL-1β, IL-6, tumor necrosis factor (TNF)
α, IFN-γ, IL-4, and IL-10 were determined by sandwich
ELISA using the monoclonal antibodies MAB501, BAF501
and recombinant rat IL-1β for IL-1β (R&DSystems, Wies-
baden, Germany) or the respective BD OptEIA Sets for all
other cytokines (BD Pharmingen, Heidelberg, Germany) in
accordance with the manufacturer's recommendations.
Data were normalized to total protein levels as determined
using the BCA-Assay (Pierce, Rockville, IL, USA) and
expressed as ng cytokine/mg total protein.
Statistics
The nonparametric Mann–Whitney (U) test was applied to
analyze differences among groups for all parameters exam-
ined. For each cytokine and time point, the levels of mRNA
and protein expression were compared with baseline levels
(day 0) and with the respective preceding time point. Cor-
relations between cytokine mRNA levels and the severity of
joint swelling in individual animals were assessed by means
of the Spearman rank correlation test. In both cases, differ-
ences were considered statistically significant for P ≤ 0.05.
Results
Clinical parameters
In both experimental series, arthritis typically developed
within 6 hours of intra-articular injection of the arthritogen
mBSA and reached a peak on day 1 (Fig. 1); swelling
started to decrease on day 3. However, a significantly
lower joint swelling in the arthritis series used for determi-
nation of protein (data not shown) allowed only a qualitative
comparison of mRNA and protein levels in the SM and the
other organs.
Generally, the following phases could be distinguished:
preclinical (day 0); acute (6 hours to day 3); transition to
chronicity (day 6). It should be considered that animals
undergoing cytokine mRNA and protein analysis before
induction of AIA (day 0) were under the influence of sys-
temic immunization with mBSA (see Materials and methods
and the next paragraph for details).
Cytokine protein levels in the prearthritis phase
For both mRNA and protein, all subsequent data are pre-
sented as fold changes in relation to the cytokine expres-
sion on day 0 (i.e. after immunization, but before induction
of arthritis). Whereas mRNA data are expressed as relative
units and are therefore not comparable among different
cytokines at any time point, cytokine protein concentrations
are expressed as ng/mg total protein and are therefore suit-
able for comparison among cytokines. Quantitative data for
day 0 of AIA are presented in Table 1.
The relative protein expression in the various organs fol-
lowed nearly identical patterns and quantitatively ranked as
follows:
SM: IL-1β > TNF-α > IFN-γ > IL-6 > IL-10 > IL-4
Ing LN: IL-1β > IL-2 > IFN-γ > TNF-α > IL-10 > IL-6 > IL-4
Spleen: IL-1β > IL-2 > TNF-α > IFN-γ > IL-6 > IL-10 > IL-4
In addition, the concentrations of all the cytokines studied
showed the highest values in the SM (approximately 2.5 to
340 ng/mg total protein), followed by those in the inguinal
LN (approximately 0.02 to 9.8 ng/mg) and spleen (approx-
imately 0.01 to 1.0 ng/mg) on day 0 and also throughout
Table 1
Cytokine protein per total protein (ng/mg) on day 0 of antigen-induced arthritis in rats
Cytokine Synovial membrane Inguinal lymph node Spleen
IL-1β 338.60 (90.78) 9.81 (2.61) 0.983 (0.117)
IL-6 20.26 (5.77) 0.10 (0.03) 0.015 (0.006)
TNF-α 80.46 (15.48) 0.71 (0.19) 0.041 (0.004)
IL-2 n.d. 1.73 (0.54) 0.054 (0.012)
IFN-γ 43.11 (9.83) 0.74 (0.21) 0.028 (0.004)
IL-4 2.47 (0.62) 0.02 (0.01) 0.007 (0.001)
IL-10 11.51 (3.49) 0.56 (0.11) 0.011 (0.001)
Values are means (standard error of the mean). n.d., not determined.Arthritis Research & Therapy    Vol 7 No 3    Pohlers et al.
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the course of AIA (Table 1, in conjunction with Fig. 3 and
Table 3, underlining the predominantly local character of
AIA.
Cytokine mRNA and protein expression in the synovial 
membrane
IL-1β. IL-1β mRNA increased sharply by 6 hours after
induction of arthritis (Fig. 2a). By days 1 and 3, the expres-
sion of this mRNA declined significantly, approaching but
still significantly exceeding 'prearthritis' levels by day 6. The
mRNA levels correlated positively with the degree of joint
swelling in individual animals (P = 0.05; Table 2). In gen-
eral, IL-1β protein levels in the SM matched the mRNA
course, with a peak 6 hours after induction (Fig. 3a). In con-
trast to the mRNA, the protein fell significantly below prear-
thritis levels already by day 1 and remained at this level until
day 6.
IL-6. Like IL-1β, IL-6 mRNA levels rose significantly by 6
hours (Fig. 2b), and declined significantly thereafter. On
day 6 the levels of this mRNA did not significantly differ
from those in the prearthritis phase. IL-6 mRNA levels cor-
related positively with the degree of joint swelling in individ-
ual animals (P  = 0.03; Table 2). Protein expression
followed the course of mRNA expression; that is, after an
initial peak at 6 hours (Fig. 3b) IL-6 dropped below prear-
thritis levels on day 1 and thereafter.
TNF-α. TNF-α mRNA levels did not significantly change
throughout the disease (although they numerically rose
above levels at immunization (Fig. 2c)). However, there was
a significant rise of protein at 6 hours after induction (Fig.
3c), followed by a reduction to below prearthritis values on
day 1 and thereafter.
IL-2. IL-2 mRNA expression underwent a massive elevation
at 6 hours, declined significantly on days 1 and 3, and dis-
appeared by day 6 (Fig. 2d). Because of the limited quantity
of SM tissue, the protein levels were not determined.
IFN-γ. IFN-γ mRNA levels were significantly increased at 6
hours and day 1 and dropped significantly by day 3 (Fig.
2e). The protein increased comcomitantly at 6 hours (Fig.
3e) but had dropped to below prearthritis levels already by
day 1.
IL-4. Whereas IL-4 mRNA was not detected (Fig. 2f), IL-4
protein was expressed at detectable but low levels. This
cytokine increased significantly by 6 hours after induction
of AIA (Fig. 3f) and then decreased to below prearthritis val-
ues by day 1.
IL-5. IL-5 mRNA peaked moderately, but significantly, by 6
hours (Fig. 2g). The protein levels were not determined.
IL-10. IL-10 mRNA was notably increased at 6 hours and
day 1 and then showed significant decreases on days 3
and 6 (Fig. 2h). The protein increased 6 hours after induc-
tion of AIA, followed by a significant decrease on day 1 and
a drop to below prearthritis values on days 3 and day 6 (Fig.
3h).
Cytokine mRNA and protein expression in the inguinal 
lymph node
IL-1β. Neither IL-1β mRNA (Fig. 4a) nor IL-1β protein
(Table 3, top) showed major changes throughout the
course of AIA (with the exception of a minor, but significant,
2-fold increase of protein by day 6 in comparison with day
0).
IL-6. IL-6 mRNA peaked significantly above prearthritis lev-
els by 6 hours after induction of AIA (Fig. 4b), but returned
to baseline levels by day 1. On day 3, that is, at the end of
the acute peak of AIA, the levels of IL-6 mRNA, although
not significantly altered on a group basis, correlated posi-
tively with the degree of joint swelling in individual animals
(P = 0.02; Table 2). No peak of protein concentrations at 6
hours was detected, but protein, too, declined significantly
by day 6 in comparison with baseline levels (Table 3, top).
TNF-α. TNF-α mRNA maintained immunization levels
throughout the acute phase of AIA but dropped signifi-
cantly by day 6 (Fig. 4c), that is, at the transition to chronic-
ity (Fig. 1); a parallel time course was observed for the
protein, though the differences did not reach significance
(Table 3, top).
IL-2. IL-2 mRNA rose significantly above immunization lev-
els by 6 hours after the induction of AIA and gradually
declined to prearthritis levels thereafter (Fig. 4d). The pro-
Figure 1
Time course of knee-joint swelling in rats with AIA used to evaluate  cytokine mRNA Time course of knee-joint swelling in rats with AIA used to evaluate 
cytokine mRNA. Values are means (n = 4 to 6); vertical bars indicate 
the standard error of the mean. The disease is characterized by rapid 
onset of acute inflammation, a peak on day 1, and a transition to chro-
nicity on day 6. **P ≤ 0.01 in comparison with day 0; ++P ≤ 0.01 in 
comparison with the preceding date. AIA, antigen-induced arthritis.
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tein showed a similar time course, though the differences
did not reach significance (Table 3, top).
IFN-γ. The levels of IFN-γ mRNA approximately doubled
throughout the acute phase of AIA in comparison with
prearthritis levels, though the increase was not statistically
significant (Fig. 4e). The protein showed a similar time
course, again without reaching significance (Table 3, top).
IL-4. IL-4 mRNA expression underwent a significant burst
on day 3 of AIA, that is, at the end of the acute phase of the
joint disease (Fig. 4f). The protein levels, however, despite
a limited increase on day 1, showed no significant changes
(Table 3, top).
IL-5. IL-5 mRNA expression paralleled that of IL-4 mRNA,
also reaching a significant peak on day 3 (Fig. 4g); the
Figure 2
Expression of mRNA of various cytokines in the synovial membrane of rats with AIA Expression of mRNA of various cytokines in the synovial membrane of rats with AIA. Expression of mRNA was assessed before the induction of anti-
gen-induced arthritis (AIA) (day 0) or afterwards (at 6 hours and on days 1, 3, and 6). Data were originally expressed as arbitrary units (1 unit = high-
est detectable dilution of the competitor fragment) and then related to the value of day 0 (fold change). Values are means;vertical bars indicate the 
standard error of the mean (n = 4 to 6 rats for each time point). Each determination was performed in duplicate. *P ≤ 0.05, **P ≤ 0.01 in comparison 
with day 0; +P ≤ 0.05, ++P ≤ 0.01 in comparison with the preceding date.
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expression of IL-4 and IL-5 appeared biphasic, however, as
indirectly documented by a drop on day 1 in comparison
with prearthritis levels (Fig. 4f,g). Protein levels for IL-5
were not determined.
IL-10. IL-10 mRNA was not detected in this organ at any
time point of the disease (Fig. 4h), but IL-10 protein was
detected at all time points, showing a significant increase
on day 1 and a decrease to prearthritis levels on day 6
(Table 3, top).
Cytokine mRNA and protein expression in the spleen
IL-1β. IL-1β mRNA levels peaked modestly and only initially,
by 6 hours (Fig. 5a). Protein levels were unchanged during
the course of arthritis (Table 3, bottom).
IL-6. IL-6 underwent a progressive elevation that reached
plateau levels between days 3 and 6 of AIA (Fig. 5b), when
the clinical signs of synovitis were already decreasing (Fig.
1). The levels of IL-6 mRNA expression correlated positively
with the degree of joint swelling (P  = 0.01; Table 2).
Although an elevation of protein levels was not detected
between days 0 and 3, a significant increase on day 6 in
comparison with day 3 partially reflected the data for the
mRNA (Table 3, bottom).
TNFα. TNF-α mRNA progressively increased to a peak on
day 3; however, the large variability among animals likely
impeded statistical significance (Fig. 5c). After an initial sig-
nificant drop at 6 hours (P = 0.05 in comparison with day
0), the protein levels reached prearthritis levels on day 1
and were slightly, but not significantly, elevated on day 6
(Table 3, bottom).
IL-2. IL-2 mRNA showed a biphasic elevation, at 6 hours in
correspondence with the beginning of synovitis, and on day
3 (Fig. 5d), coincident with the late acute phase of the dis-
ease (Fig. 1). IL-2 protein remained nearly unchanged
throughout AIA, with a slight, but significant, increase on
day 6 in comparison with day 0 and day 3 (Table 3,
bottom).
IFN-γ. IFN-γ mRNA underwent a moderate, plateau-like ele-
vation until day 3 of AIA (Fig. 5e), that is, throughout
ascending phase and acute peak of AIA (Fig. 1). As with IL-
2 protein, a slight, but significant, increase of IFN protein
was seen on day 6 in comparison with day 3 (Table 3,
bottom).
IL-4. IL-4 mRNA was not detected throughout the course
of AIA (Fig. 5f). Protein was detectable throughout all
phases, though without any significant changes (Table 3,
bottom).
IL-5. IL-5 mRNA underwent a gradual, moderate rise until
day 3 (Fig. 5g); for this cytokine, a negative correlation with
the severity of arthritis was observed on day 6 (P < 0.001;
Table 2), although the group as such showed no significant
IL-5 elevation on this date (Fig. 5g). Protein levels for IL-5
were not determined.
IL-10. IL-10 mRNA was significantly elevated in the spleen,
but only within the acute phase of AIA (6 hours) (Fig. 5h).
As with IL-5, IL-10 showed a negative correlation with the
degree of joint swelling on day 6 (P = 0.04; Table 2). There
were no significant changes of IL-10 protein levels through-
out the course of AIA (Table 3, bottom).
Table 2
Correlation between mRNA expression and severity of knee joint swelling in rats with AIA
Cytokine Day(s) Correlationa Pa ρa n
Synovial membrane
IL-1β 0–6 + 0.05 0.527 25
IL-6 0–6 + 0.03 0.405 28
Inguinal lymph node
IL-6 3 + 0.02 0.886 6
Spleen
IL-6 0–6 + 0.01 0.511 25
IL-5 6 - <0.001 1.000 4
IL-10 6 - 0.04 0.829 6
aSpearman rank correlation. +, positive; -, negative; AIA, antigen-induced arthritis.Available online http://arthritis-research.com/content/7/3/R445
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There was no significant correlation between the clinical
time course and the protein levels for any cytokine in any
organ at any time point.
Discussion
The present study documents that, in AIA, elevation of IL-
1β in the SM as well as elevations of IL-6 mRNA in SM,
inguinal LN, and spleen correlate positively with the
disease severity and that the rise of Th1-like cytokines in
the SM is massive in this model, but that this rise clearly
overlaps with early Th2-like responses, as has also been
shown by immunohistochemistry in the respective mouse
model [21].
Figure 3
Expression of proteins for various cytokines in the synovial membrane of rats with AIA Expression of proteins for various cytokines in the synovial membrane of rats with AIA. Expression of protein was assessed before the induction of 
antigen-induced arthritis (AIA) (day 0) or afterwards (at 6 hours and on days 1, 3, and 6). Data were originally expressed as ng/mg total protein and 
then related to values of day 0 (fold change; peak values in ng/mg total protein are indicated for 6 hours). Values are means; vertical bars indicate 
the standard error of the mean (n = 5 to 6 rats for each time point). *P ≤ 0.05 in comparison with day 0; +P ≤ in comparison with the preceding date.
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Local compartment
At early stages of AIA, the elevation of mRNA for IL-1β and
IL-6 is very prominent at the primary site of pathology (SM
450- to 200-fold >> LN and spleen 1.5- to 10-fold; Figs 2,
4, and 5); this is very consistent with the prominently local
character of AIA, induced by direct intra-articular injection
of the arthritogen mBSA [15]. The levels of gene activation
for these cytokines in the SM correlate positively with the
clinical severity of AIA, as has also been reported for IL-1β
and IL-6 protein in murine or rabbit AIA [5,22]. In the sys-
temic rat adjuvant arthritis, in contrast, IL-1β is far more ele-
vated in the LN than in the SM [19], in line with the different
mode of induction of the disease, which favors spread of
the arthritogen to the regional LNs [23]. Both the pathology
and the sequence of macrophage immigration in the
inflamed SM are well characterized in AIA [[24,25], and our
own observation]. However, the early profiles of IL-1β and
IL-6 mRNA do not match these kinetics. Similarly, there is
no obvious relationship with the distribution of macrophage
subpopulations, as identified by ED1, ED2, or ED3 markers
[26]. It must be considered that the normal SM in the rat
contains a number of resident macrophages [27] that, once
activated, could be responsible for the early production of
monokines in AIA; these monokines may initiate the inflam-
matory response and promote further cell immigration [28].
AIA synovitis is accompanied by a nonsignificant 6-fold
local elevation of TNF-α message (Fig. 2c), but a signifi-
cantly increased protein production (5-fold; peak level
approximately 400 ng/mg total protein; Fig. 3c). In compar-
ison with other cytokines such as IL-6 (200-fold increase of
mRNA; 4-fold increase of protein; peak level approximately
80 ng/mg total protein), TNF-α reached higher protein lev-
els despite lower fold changes of mRNA, possibly because
of a more efficient translation mechanism. Such discrepan-
cies between mRNA and protein expression have also
been found in another study, using streptococcal-cell-wall-
induced arthritis [29]: a 100,000-fold mRNA increase for
IL-6 resulted in only a 1000-fold protein elevation, whereas
the increases for TNF-α were 3.5-fold and 2-fold for mRNA
and protein, respectively.
In the SM, there were significant elevations of both IFN-γ
and IL-2 mRNA in the acute phase (Figs 2d,e; also con-
firmed for IFN-γ protein in Fig. 3e), thus indicating a com-
plete Th1-like response at a local level. The burst of these
cytokines is early and short-lasting, representing therefore
a marker of very acute disease, and supporting the concept
that anti-IL-2- or anti-IFN-γ treatments are of potential ther-
apeutic use if performed at the outbreak of disease [30,31].
The marked elevation of both IFN-γ and IL-2 mRNA at the
primary site of pathology, in contrast to the modest eleva-
tion of these lymphokines at a regional and systemic level,
is consistent with the pre-eminently local character of AIA.
Notably, this profile is practically the opposite to that of sys-
temic adjuvant arthritis, in which early IFN-γ mRNA eleva-
tion is prominent in the regional LN draining the injection
site of the arthritogen, but very modest in the SM [19].
Strong Th1-like responses, therefore, appear limited to the
site of antigen injection, occurring only upon massive expo-
Table 3
Changes (fold change relative to day 0) in cytokine protein concentrations during rat AIA
Time point IL-1β IL-6 TNF-α IL-2 IFN-γ IL-4 IL-10
Inguinal lymph node
Day 0 1.00 (0.27) 1.00 (0.26) 1.00 (0.26) 1.00 (0.31) 1.00 (0.28) 1.00 (0.25) 1.00 (0.20)
6 hours 1.67 (0.60) 0.98 (0.38) 1.93 (0.78) 1.06 (0.31) 0.98 (0.25) 1.38 (0.55) 1.60 (0.32)
Day 1 1.74 (0.58) 0.59 (0.42) 2.53 (0.78) 1.31 (0.45) 1.14 (0.34) 1.86 (0.72) 2.18* (0.49)
Day 3 1.24 (0.29) 0.40 (0.21) 1.38 (0.28) 0.66 (0.12) 0.55 (0.11) 0.53 (0.28) 1.41 (0.24)
Day 6 1.86* (0.41 0.10* (0.10) 1.87 (0.38) 0.69 (0.14) 0.81 (0.12) 0.91 (0.27) 0.89 (0.17)
Spleen
Day 0 1.00 (0.12) 1.00 (0.41) 1.00 (0.10) 1.00 (0.23) 1.00 (0.13) 1.00 (0.12) 1.00 (0.05)
6 hours 0.75 (0.09) 0.32 (0.14) 0.61* (0.04) 0.70 (0.07) 0.78 (0.04) 0.77 (0.04) 0.94 (0.06)
Day 1 0.72 (0.11) 0.41 (0.17) 0.95 (0.13) 0.84 (0.16) 0.81 (0.07) 0.80 (0.08) 0.87 (0.08)
Day 3 0.81 (0.06) 0.24 (0.14) 1.07 (0.08) 0.70 (0.13) 0.71 (0.06) 0.85 (0.06) 0.90 (0.06)
Day 6 0.67 (0.06) 0.82*+ (0.07) 1.36 (0.21) 1.10*+ (0.13) 0.91+ (0.06) 0.96 (0.10) 0.99 (0.07)
Values (fold changes) are means (standard error of the mean) (n = 5 to 6 rats for each time point). AIA, antigen-induced arthritis. *P ≤ 0.05 in 
comparison with day 0; +P ≤ 0.05 in comparison with the preceding date.Available online http://arthritis-research.com/content/7/3/R445
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sure of the local immune system to the antigen. Whether
t h e  e a r l y  I L - 2  m R N A  p e a k  i n  t h e  S M  o f  A I A  r a t s  a l s o
contributes to the development of regulatory T cells
remains to be determined [32].
Overlapping the Th1-like response, there were significant
elevations of the Th2 cytokines IL-4 (protein only; Fig. 3f),
IL-5 (mRNA; Fig. 2g; protein not determined), and IL-10
(Figs 2h and 3h). Of particular interest, IL-10 in the SM
peaks and then progressively declines until chronicity
ensues (Figs 2h and 3h). The role of IL-10 in arthritis clearly
seems a protective one, as indicated by studies on the
amelioration of collagen-induced arthritis by administration
of IL-10 or its augmentation in IL-10 knockout mice [33,34].
Figure 4
Expression of mRNA for various cytokines in the inguinal lymph nodes of rats with AIA Expression of mRNA for various cytokines in the inguinal lymph nodes of rats with AIA. Time course and other details as in Fig. 2. AIA, antigen-
induced arthritis.
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IL-10 is a Th2-like cytokine produced not only by Th1 and
Th2 cells, but also (and perhaps predominantly) by macro-
phages, probably as an autocrine factor of immune regula-
tion (reviewed in [8]). The very early rise of IL-10 in the SM
supports this view, because in this organ it coincides with
massive macrophage activation (Figs 2 and 3), which is
probably due to locally injected, arthritogenic mBSA.
The acute rise of IL-4 in the SM was detected only with
regard to protein, possibly due to the extremely sensitive
ELISA-Kit (detection limit 0.1 pg/ml) capable of detecting
very low amounts of this cytokine in the SM (2.5 ng/mg total
protein). The early expression of IL-4 seems to be important
to counteract the dramatic inflammatory response in acute
arthritis, as is shown by a protective effect of IL-4 adminis-
tration in the induction phase of CIA [35]. However, lower
acute responses but disease-promoting effects in the
chronic phase of CIA have been reported in IL-4-/- mice
[36], showing a phase-dependent, dual role of this
cytokine.
Figure 5
Expression of mRNA for various cytokines in the spleens of rats with AIA Expression of mRNA for various cytokines in the spleens of rats with AIA. Time course and details as in Fig. 2. AIA, antigen-induced arthritis.
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The acute rise of IL-5 mRNA in the SM could be IL-4-
dependent, based on the fact that IL-4 is a driving force in
many Th2-like responses [8]. Of note, early IL-5 rises have
also been observed in adjuvant arthritis [19], and, more
importantly, in Biozzi mice susceptible (but not in mice
resistant) to collagen-induced arthritis [37]. Timed IL-5- or
anti-IL-5 treatments are therefore needed to address the
proinflammatory or anti-inflammatory role of IL-5 in the
acute phase of AIA.
Systemic compartments
In spite of its prominently local character, AIA is accompa-
nied by a peak of IL-6 mRNA in the inguinal LN at 6 hours
(Fig. 4b), and an elevation of this mRNA in the spleen (6
hours, day 3, and day 6; Fig. 5b), in the latter case signifi-
cantly correlated with the severity of disease (Table 2). This
rise is maintained throughout the chronic phase, similarly to
IL-6 protein in the serum of AIA [38] and adjuvant arthritis
rats [39], and in analogy to findings in the synovial fluid of
RA patients [40]. Whereas the acute rise of LN/spleen IL-
6 is consistent with the acute-phase response typical of
early AIA [41], the contribution of IL-6 to chronicity remains
uncertain [42,43], perhaps because it can be produced not
only by macrophages but also by Th2 cells [8,39].
TNF-α mRNA can be clearly documented in the regional LN
and spleen (Figs 4c and 5c), in temporal coincidence with
the severity of the joint swelling (Fig. 1), though with high
variability from animal to animal, resulting in a lack of statis-
tical significance. In AIA, therefore, the role of systemic
TNF-α appears marginal, at least in relation to other
cytokines, as has also been shown by the fact that suc-
cessful anti-CD4 therapy reduced IL-6, but not TNF-α lev-
els in local and systemic compartments [5]. This is at odds
with more systemic models of arthritis, such as collagen-
induced and adjuvant arthritis [19,44], in which there is
highly significant TNF-α elevation in LN and/or spleen.
Spleen TNF-α, in particular, is significantly correlated with
the severity of the wasting syndrome in adjuvant arthritis
[45]. The modesty of spleen TNF-α changes in AIA (Fig.
5c), therefore, is consistent with the lack of a wasting syn-
drome in this model [17].
Both inguinal LN and spleen showed an increase of IL-2
mRNA in the acute phase of AIA (Figs 4d and 5d), similar
to a significant rise of IFN-γ in the spleen (Fig. 5e). This is
clearly in line with the concept of Th1 dominance in AIA, as
is also emphasized by the reduced levels of these Th1
cytokines in spleen and LN upon successful anti-CD4 treat-
ment of AIA in mice [4]. The second elevation of IL-2 and
IFN-γ in the spleen just before the transition to chronicity is
similar to the situation in rat adjuvant arthritis [19], and sug-
gests that recruitment of fresh, possibly disease-control-
ling, regulatory T cells [17,32] may have a systemic
component even in the predominantly local AIA.
Although IL-4 mRNA underwent no changes in the spleen,
it rose significantly in the inguinal LN on day 3 (Fig. 4f). Fur-
thermore, there was a significant elevation of IL-5 mRNA in
spleen and inguinal LN on day 3. Both findings are consist-
ent with the transition to a regulatory phase of T-cell func-
tion in anticipation of chronicity. This time point may
therefore represent the turning point of the disease, when
LN-generated Th2-like responses may gradually replace
Th1-like processes, or, according to the present data, when
the Th1/Th2-like balance shifts in favor of Th2-like patterns
[46]. The lack of significant elevation of Th2-like cytokines
in lymphoid organs at the protein level may be due to the
relatively weak clinical arthritis in this experimental series.
Overlap of Th1-like and Th2-like responses
Besides somewhat obvious Th2-like elevations in advance
of chronicity (see above), in line with the expected regula-
tory properties of this group of cytokines [8,47,48], clear
Th2-like peaks markedly overlap with the initial Th1-like
surge. In the LN, the early Th2-like rise may include not only
IL-5 and IL-10, but also IL-6, inasmuch as this cytokine can
be produced by Th2-like cells [8] and not only by macro-
phages, which are modestly activated in this organ (Fig.
4a–c). These findings document that a sharp Th1/Th2 divi-
sion, valid for some other systems [8], does not automati-
cally apply to in vivo models of autoimmunity [10], including
other models of arthritis [19,36]. The biological relevance
of the early Th2-like rise in the SM and at systemic sites
remains however unclear, that is, whether it contributes to
inflammation or rather represents an attempt to limit the
acute inflammatory insult [8].
The Th1-like/Th2-like responses overlap with some degree
of anatomical segregation. While in the SM and spleen the
expression of mRNA for IL-2 and IFN-γ overlaps with that of
IL-5 and IL-10, the inguinal LN shows an overlap of mRNA
for IL-2 with IL-4 and IL-5. A clear anatomical segregation
of Th1-like/Th2-like responses, although in different
patterns, is seen also in rat adjuvant arthritis [19]. The ana-
tomic location of these responses varies, however, in the
two models; the knee monoarticular arthritis in AIA seems
to require a more regionally confined crosstalk with the
inguinal LN, whereas the systemic adjuvant-induced pol-
ysynovitis requires a much stronger involvement of the
spleen, the organ in which potentially regulatory T-cell
cytokine responses appear generated.
Conclusion
The present study documents that the course of AIA is
characterized by organ-specific overlaps of Th1-like and
Th2-like responses. Activation of synovial macrophages
and T cells is prominent in this prevalently local model of
arthritis, although regional and systemic factors may also
contribute to the disease processes. The cytokine patterns
share some features with systemic adjuvant arthritis,Arthritis Research & Therapy    Vol 7 No 3    Pohlers et al.
R456
although there are several clear differences, conceivably
imputable to pathogenetic differences between the two
models.
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